Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

  • CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

CIDP Assessment Tools: Grip Strength
Jeffrey A. Allen, MD
University of Minnesota
01:52 MIN
  • CIDP
Listen to a discussion about Discussing tools that are commonly used to measure grip strength in CIDP
Guillain-Barre Syndrome (GBS): Typical and Atypical Clinical Presentations
Thomas Harbo, MD, PhD
Aarhus University Hospital in Aarhus, Denmark
15:18 MIN
  • CIDP
  • GBS
Learn more about the importance of understanding typical and atypical presentations of GBS, including features of clinically distinct variants and subtypes, proper diagnosis, and initiation of appropriate treatment.
DOWNLOAD PDF
Clinical Studies for the Treatment of CIDP with Immunoglobulin
Claudia Sommer, MD
University of Würzburg, Würzburg, Germany
9:35 MIN
  • CIDP
  • MMN

Discover the results of two recent clinical studies of IVIg treatments for CIDP.

DOWNLOAD PDF
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
15:31 MIN
  • CIDP
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP
DOWNLOAD PDF
NOW PLAYING
01:52
CIDP Assessment Tools: Grip Strength
Listen to a discussion about Discussing tools that are commonly used to measure grip strength in CIDP
NOW PLAYING
15:18
Guillain-Barre Syndrome (GBS): Typical and Atypical Clinical Presentations
Learn more about the importance of understanding typical and atypical presentations of GBS, including features of clinically distinct variants and subtypes, proper diagnosis, and initiation of appropriate treatment.
NOW PLAYING
9:35
Clinical Studies for the Treatment of CIDP with Immunoglobulin

Discover the results of two recent clinical studies of IVIg treatments for CIDP.

NOW PLAYING
15:31
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Poly...
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP

Our Experts on CIDP

Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

Michael Lunn, PhD
Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

  • CIDP

Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery.

Peter Donofrio, MD
Vanderbilt University Medical Center, Nashville, TN, USA
Peter Donofrio, MD
Peter Donofrio, MD
Vanderbilt University Medical Center, Nashville, TN, USA
  • CIDP
  • GBS
Peter D. Donofrio, M.D. is a Professor of Neurology at Vanderbilt University Medical Center. He is a graduate of The Ohio State University School of Medicine and pursued a residency in neurology and a neuromuscular fellowship at the University of Michigan.
Van den Bergh, MD PhD
University Hospital Saint-Luc, Brussels, Belgium
Peter Van den Bergh, MD PhD
Van den Bergh, MD PhD
University Hospital Saint-Luc, Brussels, Belgium
  • CIDP

Peter Van den Bergh is Professor of Neurology at the Université Catholique de Louvain and Director of the Neuromuscular Centre of Reference of the Cliniques Universitaires Saint-Luc, Brussels, Belgium.

Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
Mel Berger, MD, PhD
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
  • CIDP
Mel Berger is a Senior Director, Medical Research Strategy at CSL and Adjunct Professor of Pediatrics and Pathology, Case Western Reserve University. He earned his undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University in Cleveland.
What is Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP)?
READ MORE
What are the symptoms of CIDP?
READ MORE
How is CIDP treated?
READ MORE

Slides & Posters about CIDP

Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing
PDF | 1.4 MB
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-...
PDF | 3.8 MB
Overview and Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
PDF | 656 KB
Incidence of GBS and CIDP Following Influenza Vaccination
PDF | 155 KB
Back to Top